Eli Lilly and Company $LLY Holdings Trimmed by Providence Financial Advisors LLC

Providence Financial Advisors LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 21.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,118 shares of the company’s stock after selling 579 shares during the quarter. Eli Lilly and Company accounts for 1.8% of Providence Financial Advisors LLC’s portfolio, making the stock its 11th largest position. Providence Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $2,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Torren Management LLC grew its holdings in shares of Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares during the last quarter. Foresight Capital Management Advisors Inc. bought a new position in Eli Lilly and Company during the 3rd quarter valued at about $49,000. AlphaCentric Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at about $42,000. Finally, Caitlin John LLC acquired a new position in Eli Lilly and Company in the second quarter valued at about $64,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,444.05 on Monday. The stock has a market capitalization of $1.36 trillion, a P/E ratio of 46.87, a P/E/G ratio of 1.73 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,460.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The business has a 50-day moving average price of $1,242.25 and a two-hundred day moving average price of $1,110.30.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the firm earned $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Analysts Set New Price Targets

Several brokerages have weighed in on LLY. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Sanford C. Bernstein restated an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a research report on Monday, October 26th. Finally, Argus increased their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Read Our Latest Report on Eli Lilly and Company

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.